Concurrent Cross-Sectional and Longitudinal Analyses of Multivariate White Matter Profiles and Clinical Functioning in Pre-Diagnosis Huntington Disease
Restricted accessResearch articleFirst published online 2019
Concurrent Cross-Sectional and Longitudinal Analyses of Multivariate White Matter Profiles and Clinical Functioning in Pre-Diagnosis Huntington Disease
Gray matter (GM) atrophy in the striatum and across the brain is a consistently reported feature of the Huntington Disease (HD) prodrome. More recently, widespread prodromal white matter (WM) degradation has also been detected. However, longitudinal WM studies are limited and conflicting, and most analyses comparing WM and clinical functioning have also been cross-sectional.
Objective:
We simultaneously assessed changes in WM and cognitive and motor functioning at various prodromal HD stages.
Methods:
Data from 1,336 (1,047 prodromal, 289 control) PREDICT-HD participants were analyzed (3,700 sessions). MRI images were used to create GM, WM, and cerebrospinal fluid probability maps. Using source-based morphometry, independent component analysis was applied to WM probability maps to extract covarying spatial patterns and their subject profiles. WM profiles were analyzed in two sets of linear mixed model (LMM) analyses: one to compare WM profiles across groups cross-sectionally and longitudinally, and one to concurrently compare WM profiles and clinical variables cross-sectionally and longitudinally within each group.
Results:
Findings illustrate widespread prodromal changes in GM-adjacent-WM, with premotor, supplementary motor, middle frontal and striatal changes early in the prodrome that subsequently extend sub-gyrally with progression. Motor functioning agreed most with WM until the near-onset prodromal stage, when Stroop interference was the best WM indicator. Across groups, Trail-Making Test part A outperformed other cognitive variables in its similarity to WM, particularly cross-sectionally.
Conclusions:
Results suggest that distinct regions coincide with cognitive compared to motor functioning. Furthermore, at different prodromal stages, distinct regions appear to align best with clinical functioning. Thus, the informativeness of clinical measures may vary according to the type of data available (cross-sectional or longitudinal) as well as age and CAG-number.
PaulsenJS, LongJD, JohnsonHJ, AylwardEH, RossCA, WilliamsJK, et al.Clinical and biomarker changes in premanifest Huntington disease show trial feasibility: A decade of the PREDICT-HD Study. Front Aging Neurosci. 2014;6:78.
2.
HarringtonDL, LiuD, SmithMM, MillsJA, LongJD, AylwardEH, et al.Neuroanatomical correlates of cognitive functioning in prodromal Huntington disease. Brain Behav. 2014;4(1):29–40.
3.
PaulsenJS. Cognitive impairment in Huntington disease: Diagnosis and treatment. Curr Neurol Neurosci Rep. 2011;11(5):474–83.
4.
LazicSE, GoodmanAO, GroteHE, BlakemoreC, MortonAJ, HannanAJ, et al. Olfactory abnormalities in Huntington’s disease: Decreased plasticity in the primary olfactory cortex of R6/1 transgenic mice and reduced olfactory discrimination in patients. Brain Res. 2007;1151:219–26.
5.
DoganI, SaBC, MirzazadeS, KleimanA, WernerCJ, PohlA, et al. Neural correlates of impaired emotion processing in manifest Huntington’s disease. Soc Cogn Affect Neurosci.2014;9(5):671–80.
6.
KalkhovenC, SennefC, PeetersA, van den BosR. Risk-taking and pathological gambling behavior in Huntington’s disease. Front Behav Neurosci. 2014;8:103.
7.
RawlinsMD, WexlerNS, WexlerAR, TabriziSJ, DouglasI, EvansSJ, et al. The prevalence of Huntington’s disease. Neuroepidemiology. 2016;46(2):144–53.
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. Cell. 1993;72(6):971–83.
LongJD, PaulsenJS, Group P-HIaCotHS. Multivariate prediction of motor diagnosis in Huntington’s disease: 12 years of PREDICT-HD. Mov Disord. 2015;30(12):1664–72.
12.
ZhangY, LongJD, MillsJA, WarnerJH, LuW, PaulsenJS, et al. Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am J Med Genet B Neuropsychiatr Genet. 2011;156B(7):751–63.
13.
BiglanKM, ZhangY, LongJD, GeschwindM, KangGA, KilloranA, et al. Refining the diagnosis of Huntington disease: The PREDICT-HD study. Front Aging Neurosci. 2013;5:12.
14.
CiarochiJA, CalhounVD, LourensS, LongJD, JohnsonHJ, BockholtHJ, et al. Patterns of co-occurring gray matter concentration loss across the Huntington disease prodrome. Front Neurol. 2016;7:147.
15.
PaulsenJS, LongJD, RossCA, HarringtonDL, ErwinCJ, WilliamsJK, et al. Prediction of manifest Huntington’s disease with clinical and imaging measures: A prospective observational study. Lancet Neurol. 2014;13(12):1193–201.
16.
AylwardEH, HarringtonDL, MillsJA, NopoulosPC, RossCA, LongJD, et al. Regional atrophy associated with cognitive and motor function in prodromal Huntington disease. J Huntingtons Dis. 2013;2(4):477–89.
17.
MisiuraMB, LourensS, CalhounVD, LongJ, BockholtJ, JohnsonH, et al. Cognitive control, learning, and clinical motor ratings are most highly associated with basal ganglia brain volumes in the premanifest Huntington’s disease phenotype. J Int Neuropsychol Soc. 2017;23(2):159–70.
18.
EspinozaFA, TurnerJA, VergaraVM, MillerRL, MennigenE, LiuJ, et al. Whole-brain connectivity in a large study of Huntington’s disease gene mutation carriers and healthy controls. Brain Connect. 2018;8(3):166–78.
19.
TabriziSJ, LangbehnDR, LeavittBR, RoosRA, DurrA, CraufurdD, et al. Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data. Lancet Neurol. 2009;8(9):791–801.
20.
TabriziSJ, ScahillRI, DurrA, RoosRA, LeavittBR, JonesR, et al. Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: The 12-month longitudinal analysis. Lancet Neurol. 2011;10(1):31–42.
21.
TabriziSJ, ReilmannR, RoosRA, DurrA, LeavittB, OwenG, et al. Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: Analysis of 24 month observational data. Lancet Neurol. 2012;11(1):42–53.
22.
FariaAV, RatnanatherJT, TwardDJ, LeeDS, van den NoortF, WuD, et al. Linking white matter and deep gray matter alterations in premanifest Huntington disease. Neuroimage Clin. 2016;11:450–60.
23.
WuD, FariaAV, YounesL, MoriS, BrownT, JohnsonH, et al. Mapping the order and pattern of brain structural MRI changes using change-point analysis in premanifest Huntington’s disease. Hum Brain Mapp. 2017;38(10):5035–50.
24.
PoudelGR, StoutJC, DomínguezD JF, SalmonL, ChurchyardA, ChuaP, et al. White matter connectivity reflects clinical and cognitive status in Huntington’s disease. Neurobiol Dis. 2014;65:180–7.
25.
ShafferJJ, GhayoorA, LongJD, KimRE, LourensS, O’DonnellLJ, et al. Longitudinal diffusion changes in prodromal and early HD: Evidence of white-matter tract deterioration. Hum Brain Mapp. 2017;38(3):1460–77.
26.
OrthM, GregoryS, ScahillRI, MayerIS, MinkovaL, KlöppelS, et al. Natural variation in sensory-motor white matter organization influences manifestations of Huntington’s disease. Hum Brain Mapp. 2016;37(12):4615–28.
27.
PaulsenJS, NopoulosPC, AylwardE, RossCA, JohnsonH, MagnottaVA, et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull. 2010;82(3-4):201–7.
28.
PaulsenJS, MagnottaVA, MikosAE, PaulsonHL, PenzinerE, AndreasenNC, et al. Brain structure in preclinical Huntington’s disease. Biol Psychiatry. 2006;59(1):57–63.
29.
CrawfordHE, HobbsNZ, KeoghR, LangbehnDR, FrostC, JohnsonH, et al. Corpus callosal atrophy in premanifest and early Huntington’s disease. J Huntingtons Dis. 2013;2(4):517–26.
30.
MagnottaVA, KimJ, KoscikT, BeglingerLJ, EspinsoD, LangbehnD, et al. Diffusion tensor imaging in preclinical Huntington’s disease. Brain Imaging Behav. 2009;3(1):77–84.
31.
RosasHD, TuchDS, HeveloneND, ZaletaAK, VangelM, HerschSM, et al. Diffusion tensor imaging in presymptomatic and early Huntington’s disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord. 2006;21(9):1317–25.
32.
StoffersD, SheldonS, KupermanJM, GoldsteinJ, Corey-BloomJ, AronAR. Contrasting gray and white matter changes in preclinical Huntington disease: An MRI study. Neurology. 2010;74(15):1208–16.
33.
HarringtonDL, LongJD, DurgerianS, MouranyL, KoenigK, Bonner-JacksonA, et al. Cross-sectional and longitudinal multimodal structural imaging in prodromal Huntington’s disease. Mov Disord. 2016;31(11):1664–75.
34.
PhillipsO, SquitieriF, Sanchez-CastanedaC, ElifaniF, CaltagironeC, SabatiniU, et al. Deep white matter in Huntington’s disease. PLoS One. 2014;9(10):e109676.
35.
PhillipsO, Sanchez-CastanedaC, ElifaniF, MaglioneV, Di PardoA, CaltagironeC, et al. Tractography of the corpus callosum in Huntington’s disease. PLoS One. 2013;8(9):e73280.
36.
MatsuiJT, VaidyaJG, JohnsonHJ, MagnottaVA, LongJD, MillsJA, et al. Diffusion weighted imaging of prefrontal cortex in prodromal Huntington’s disease. Hum Brain Mapp. 2014;35(4):1562–73.
37.
AylwardEH, NopoulosPC, RossCA, LangbehnDR, PiersonRK, MillsJA, et al. Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry. 2011;82(4):405–10.
38.
PoudelGR, StoutJC, Domínguez DJF, ChurchyardA, ChuaP, EganGF, et al. Longitudinal change in white matter microstructure in Huntington’s disease: The IMAGE-HD study. Neurobiol Dis. 2015;74:406–12.
39.
OdishOF, LeemansA, ReijntjesRH, van den BogaardSJ, DumasEM, WolterbeekR, et al. Microstructural brain abnormalities in Huntington’s disease: A two-year follow-up. Hum Brain Mapp. 2015;36(6):2061–74.
40.
MatsuiJT, VaidyaJG, WassermannD, KimRE, MagnottaVA, JohnsonHJ, et al. Prefrontal cortex white matter tracts in prodromal Huntington disease. Hum Brain Mapp. 2015;36(10):3717–32.
41.
PappKV, SnyderPJ, MillsJA, DuffK, WesterveltHJ, LongJD, et al. Measuring executive dysfunction longitudinally and in relation to genetic burden, brain volumetrics, and depression in prodromal Huntington disease. Arch Clin Neuropsychol. 2013;28(2):156–68.
42.
XuL, GrothKM, PearlsonG, SchretlenDJ, CalhounVD. Source-based morphometry: The use of independent component analysis to identify gray matter differences with application to schizophrenia. Hum Brain Mapp. 2009;30(3):711–24.
43.
GorgolewskiK, BurnsCD, MadisonC, ClarkD, HalchenkoYO, WaskomML, et al. Nipype: A flexible, lightweight and extensible neuroimaging data processing framework in python. Front Neuroinform. 2011;5:13.
44.
AvantsBB, TustisonNJ, SongG, CookPA, KleinA, GeeJC. A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage. 2011;54(3):2033–44.
45.
Young KimE, JohnsonHJ. Robust multi-site MR data processing: Iterative optimization of bias correction, tissue classification, and registration. Front Neuroinform. 2013;7:29.
46.
GhayoorA, PaulsenJS, Kim, EYR, JohnsonHJ. Tissue classification of large-scale multi-site MR data using fuzzy k-nearest neighbor method. Proc SPIE Med Imaging. 2016;9784:97841V.
47.
GhayoorA, VaidyaJG, JohnsonHJ. Robust automated constellation-based landmark detection in human brain imaging. Neuroimage. 2018;170:471–81.
48.
WechslerD. Manual for the Wechsler Adult Intelligence Scale. Oxford, England: Psychological Corporation; 1955.
49.
SmithA. Symbol Digit Modalities Test (SDMT) Manual (Revised). Los Angeles, CA: Western Psychological Services.; 1982.
50.
StroopJR. Studies of interference in serial verbal reactions.J Exp Psychol. 1935;18(6):643–62.
51.
O’RourkeJJ, BeglingerLJ, SmithMM, MillsJ, MoserDJ, RoweKC, et al. The Trail Making Test in prodromal Huntington disease: Contributions of disease progression to test performance. J Clin Exp Neuropsychol. 2011;33(5):567–79.
52.
ReitanR. Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills. 1958;8:271–6.
53.
Genetic Modifiers of Huntington’s Disease (GeM-HD) Consortium. Identification of genetic factors that modify clinical onset of Huntington’s disease. Cell. 2015;162(3):516–26.
54.
GuptaCN, CalhounVD, RachakondaS, ChenJ, PatelV, LiuJ, et al. Patterns of gray matter abnormalities in schizophrenia based on an international mega-analysis. Schizophr Bull. 2015;41(5):1133–42.
55.
SegallJM, AllenEA, JungRE, ErhardtEB, ArjaSK, KiehlK, et al. Correspondence between structure and function in the human brain at rest. Front Neuroinform. 2012;6:10.
56.
LiYO, AdaliT, CalhounVD. Estimating the number of independent components for functional magnetic resonance imaging data. Hum Brain Mapp. 2007;28(11):1251–66.
57.
HimbergJ, HyvärinenA, EspositoF. Validating the independent components of neuroimaging time series via clustering and visualization. Neuroimage. 2004;22(3):1214–22.
58.
MaS, CorreaNM, LiXL, EicheleT, CalhounVD, AdaliT. Automatic identification of functional clusters in FMRI data using spatial dependence. IEEE Trans Biomed Eng. 2011;58(12):3406–17.
59.
VerbekeG, MolenberghsG. Linear Mixed Models for Longitudinal Data. New York: Springer; 2000.
60.
LongJD. Longitudinal Data Analysis for the Behavioral Sciences Using R. Thousand Oaks, California: SAGE Publications, Inc.; 2011.
61.
LambrecqV, LangbourN, GuehlD, BioulacB, BurbaudP, RotgeJY. Evolution of brain gray matter loss in Huntington’s disease: A meta-analysis. Eur J Neurol. 2013;20(2):315–21.
62.
MühlauM, GaserC, WohlschlägerAM, WeindlA, StädtlerM, ValetM, et al. Striatal gray matter loss in Huntington’s disease is leftward biased. Mov Disord. 2007;22(8):1169–73.
63.
KlöppelS, GregoryS, SchellerE, MinkovaL, RaziA, DurrA, et al. Compensation in preclinical Huntington’s disease: Evidence from the Track-On HD Study. EBioMedicine. 2015;2(10):1420–9.
64.
AylwardEH, CodoriAM, BartaPE, PearlsonGD, HarrisGJ, BrandtJ. Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol. 1996;53(12):1293–6.
65.
HarrisGJ, PearlsonGD, PeyserCE, AylwardEH, RobertsJ, BartaPE, et al. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington’s disease. Ann Neurol. 1992;31(1):69–75.
66.
TabriziSJ, ScahillRI, OwenG, DurrA, LeavittBR, RoosRA, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington’s disease in the TRACK-HD study: Analysis of 36-month observational data. Lancet Neurol. 2013;12(7):637–49.
67.
CiarochiJA, LiuJ, CalhounV, JohnsonH, MisiuraM, BockholtHJ, et al. High and low levels of an NTRK2-driven genetic profile affect motor- and cognition-associated frontal gray matter in prodromal Huntington’s disease. Brain Sci. 2018;8(7):E116.
68.
RosasHD, SalatDH, LeeSY, ZaletaAK, PappuV, FischlB, et al. Cerebral cortex and the clinical expression of Huntington’s disease: Complexity and heterogeneity. Brain. 2008;131(Pt 4):1057–68.
69.
Sánchez-CastañedaC, de PasqualeF, CaravassoCF, MaranoM, MaffiS, MiglioreS, et al. Resting-state connectivity and modulated somatomotor and default-mode networks in Huntington disease. CNS Neurosci Ther. 2017;23(6):488–97.
70.
WernerCJ, DoganI, SaBC, MirzazadeS, SchieferJ, ShahNJ, et al. Altered resting-state connectivity in Huntington’s disease. Hum Brain Mapp. 2014;35(6):2582–93.
71.
KoenigKA, LoweMJ, HarringtonDL, LinJ, DurgerianS, MouranyL, et al. Functional connectivity of primary motor cortex is dependent on genetic burden in prodromal Huntington disease. Brain Connect. 2014;4(7):535–46.
72.
MacdonaldV, HallidayGM, TrentRJ, McCuskerEA. Significant loss of pyramidal neurons in the angular gyrus of patients with Huntington’s disease. Neuropathol Appl Neurobiol. 1997;23(6):492–5.
73.
JarboK, VerstynenTD. Converging structural and functional connectivity of orbitofrontal, dorsolateral prefrontal, and posterior parietal cortex in the human striatum. J Neurosci. 2015;35(9):3865–78.
74.
Fennema-NotestineC, ArchibaldSL, JacobsonMW, Corey-BloomJ, PaulsenJS, PeavyGM, et al. In vivo evidence of cerebellar atrophy and cerebral white matter loss in Huntington disease. Neurology. 2004;63(6):989–95.
75.
WolfRC, ThomannPA, SambataroF, WolfND, VasicN, LandwehrmeyerGB, et al. Abnormal cerebellar volume and corticocerebellar dysfunction in early manifest Huntington’s disease. J Neurol. 2015;262(4):859–69.
76.
ReesEM, FarmerR, ColeJH, HaiderS, DurrA, LandwehrmeyerB, et al. Cerebellar abnormalities in Huntington’s disease: A role in motor and psychiatric impairment?Mov Disord. 2014;29(13):1648–54.
77.
RübU, HocheF, BruntER, HeinsenH, SeidelK, Del TurcoD, et al. Degeneration of the cerebellum in Huntington’s disease (HD): Possible relevance for the clinical picture and potential gateway to pathological mechanisms of the disease process. Brain Pathol. 2013;23(2):165–77.
78.
Georgiou-KaristianisN, SritharanA, FarrowM, CunningtonR, StoutJ, BradshawJ, et al. Increased cortical recruitment in Huntington’s disease using a Simon task. Neuropsychologia. 2007;45(8):1791–800.
79.
LiuW, YangJ, ChenK, LuoC, BurgunderJ, GongQ, et al. Resting-state fMRI reveals potential neural correlates of impaired cognition in Huntington’s disease. Parkinsonism Relat Disord. 2016;27:41–6.
80.
RosasHD, HeveloneND, ZaletaAK, GreveDN, SalatDH, FischlB. Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology. 2005;65(5):745–7.
81.
BartensteinP, WeindlA, SpiegelS, BoeckerH, WenzelR, Ceballos-BaumannAO, et al. Central motor processing in Huntington’s disease. A PET study. Brain. 1997;120 (Pt 9):1553–67.
82.
WeeksRA, Ceballos-BaumannA, PicciniP, BoeckerH, HardingAE, BrooksDJ. Cortical control of movement in Huntington’s disease. A PET activation study. Brain. 1997;120 (Pt 9):1569–78.
83.
OdishOFF, ReijntjesRHAM, van den BogaardSJA, RoosRAC, LeemansA. Progressive microstructural changes of the occipital cortex in Huntington’s disease. Brain Imaging Behav. 2018;12(6):1786–94.
84.
ChenJ, LiuJ, CalhounVD, Arias-VasquezA, ZwiersMP, GuptaCN, et al. Exploration of scanning effects in multi-site structural MRI studies. J Neurosci Methods. 2014;230:37–50.
85.
MagnottaVA, MatsuiJT, LiuD, JohnsonHJ, LongJD, BolsterBD, et al. Multicenter reliability of diffusion tensor imaging. Brain Connect. 2012;2(6):345–55.
